Beyond Air Q3 FY2023 net loss $12.7M; expects first LungFit PH sales in March quarter

Beyond Air, Inc.

2024-Q3 EPS reported -$1.19

Net loss attributable to shareholders $12.7M ($0.43/share) vs $7.7M ($0.29) a year ago.
Cash and equivalents $63.2M; quarterly cash burn $9.3M in line with $8.0-10.0M guidance.
R&D expenses $5.0M (+99% YoY) from Beyond Cancer scale-up; G&A $8.9M (+82% YoY) for commercial launch.
CE Mark for LungFit PH expected H1 FY2024; PMA supplement for cardiac label in H1 CY2023.
US VCAP trial planned Q4 CY2023; NTM trial in H2 FY2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Beyond Air, Inc. reported third fiscal quarter ended December 31, 2022 results: net income GAAP net loss of $13.8 million, of which $12.7 million, or ($0.43) per share, was attributable to the shareholders of Be, EPS ($0.43) per share.

Period: third fiscal quarter ended December 31, 2022
Net income: GAAP net loss of $13.8 million, of which $12.7 million, or ($0.43) per share, was attributable to the shareholders of Be
EPS: ($0.43) per share
Result: reported results

Exact text from the filing

For the fiscal quarter ended December 31, 2022, the Company had a GAAP net loss of $13.8 million, of which $12.7 million, or ($0.43) per share, was attributable to the shareholders of Beyond Air, Inc.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Beyond Air, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-004522

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.